Determining a private company’s value means estimating how and when it might be able to start and then complete successful clinical trials, or when it will get a regulator’s approval to manufacture and sell a drug.
But the coronavirus pandemic means every step in that process has become far more uncertain in the past two months — and that added uncertainty means some biotech companies may be worth less on paper than they were before.
About the Author Reprints
